1. Home
  2. VRDN
  3. VRDN News

Latest Viridian Therapeutics Inc. (VRDN) News on June 1, 2025

Viridian Therapeutics to Participate in Upcoming June Investor Conferences
VRDN

Business Wire

2 days ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
VRDN

Business Wire

12 days ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
VRDN

Business Wire

24 days ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations
VRDN

Simply Wall St.

25 days ago

Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
VRDN

Business Wire

a month ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

a month ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
VRDN

Business Wire

2 months ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

3 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
VRDN

Simply Wall St.

3 months ago

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
VRDN

Business Wire

3 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

4 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
VRDN

Business Wire

5 months ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?
VRDN

Simply Wall St.

5 months ago

Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?

Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
VRDN

TipRanks

5 months ago

Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints

Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
VRDN

Investor's Business Daily

5 months ago

Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
VRDN

Investor's Business Daily

6 months ago

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
VRDN

Business Wire

6 months ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
VRDN

Business Wire

6 months ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

6 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
VRDN

Simply Wall St.

7 months ago

Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
VRDN

Business Wire

7 months ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

7 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings
VRDN

Simply Wall St.

7 months ago

Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings

VRDN

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
VRDN

Business Wire

9 months ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
VRDN

Business Wire

9 months ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
VRDN

Business Wire

9 months ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
VRDN

Business Wire

9 months ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

9 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
VRDN

Business Wire

10 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

10 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks
VRDN

TipRanks

10 months ago

Goldman Sachs Predicts up to 165% Surge for These 2 ‘Strong Buy’ Stocks

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
VRDN

Business Wire

10 months ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics to Participate in Upcoming May Investor Conferences
VRDN

Business Wire

a year ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
VRDN

Simply Wall St.

a year ago

Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

VRDN

GuruFocus.com

a year ago

Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
VRDN

GuruFocus.com

a year ago

Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
VRDN

Business Wire

a year ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
VRDN

Business Wire

a year ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
VRDN

Business Wire

a year ago

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations
VRDN

Simply Wall St.

a year ago

Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
VRDN

Business Wire

a year ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
VRDN

Business Wire

a year ago

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

VRDN

Investing.com

a year ago

Dow futures rebound after Fed-inspired losses; tech earnings in spotlight

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit
VRDN

Barrons.com

a year ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Analysts Have Made A Financial Statement On First Busey Corporation's (NASDAQ:BUSE) Annual Report
VRDN

Simply Wall St.

a year ago

Analysts Have Made A Financial Statement On First Busey Corporation's (NASDAQ:BUSE) Annual Report

Virtu Financial (VIRT) Q4 Earnings Miss on Higher Expenses
VRDN

Zacks

a year ago

Virtu Financial (VIRT) Q4 Earnings Miss on Higher Expenses

VRDN

Business Wire

a year ago

Hamilton Insurance Group, Ltd. to Report Fourth Quarter 2023 Financial Results on March 6, 2024

VRDN

GuruFocus.com

a year ago

First Busey Corp (BUSE) Reports Mixed Q4 Earnings Amid Strategic Acquisitions and Balance Sheet ...

DuPont Stock Plunges on Lousy Guidance. Blame China and ‘Destocking.’
VRDN

Barrons.com

a year ago

DuPont Stock Plunges on Lousy Guidance. Blame China and ‘Destocking.’

Compared to Estimates, First Busey (BUSE) Q4 Earnings: A Look at Key Metrics
VRDN

Zacks

a year ago

Compared to Estimates, First Busey (BUSE) Q4 Earnings: A Look at Key Metrics

Grow Financial Federal Credit Union Streamlines, Enhances Self-Service Banking Through NCR Atleos Partnership
VRDN

Business Wire

a year ago

Grow Financial Federal Credit Union Streamlines, Enhances Self-Service Banking Through NCR Atleos Partnership

VRDN

Investing.com

a year ago

Coinbase Global cut at JPMorgan amid Bitcoin ETF skepticism: 4 big analyst cuts

Hamilton Appoints Jamie Secor as Chief Underwriting Officer of US E&S Insurer Hamilton Select
VRDN

Business Wire

a year ago

Hamilton Appoints Jamie Secor as Chief Underwriting Officer of US E&S Insurer Hamilton Select

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Q3 Traditional Fast Food Earnings: Arcos Dorados (NYSE:ARCO) Impresses
VRDN

StockStory

a year ago

Q3 Traditional Fast Food Earnings: Arcos Dorados (NYSE:ARCO) Impresses

Howard Hughes, Carrier, and More Stocks See Action From Activist Investors
VRDN

Barrons.com

a year ago

Howard Hughes, Carrier, and More Stocks See Action From Activist Investors

VRDN

Newsfile

a year ago

Equinox Gold Produces 564,500 Ounces of Gold in 2023, Reports 155,000 Ounces of Gold Produced in Fourth Quarter

Is It Too Late To Consider Buying CSG Systems International, Inc. (NASDAQ:CSGS)?
VRDN

Simply Wall St.

a year ago

Is It Too Late To Consider Buying CSG Systems International, Inc. (NASDAQ:CSGS)?

Tiger Woods Breaks Up With Nike. Will On Holding Be His New Home?
VRDN

Motley Fool

a year ago

Tiger Woods Breaks Up With Nike. Will On Holding Be His New Home?

Shareholders in National Vision Holdings (NASDAQ:EYE) are in the red if they invested three years ago
VRDN

Simply Wall St.

a year ago

Shareholders in National Vision Holdings (NASDAQ:EYE) are in the red if they invested three years ago

Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?
VRDN

Simply Wall St.

a year ago

Is There An Opportunity With Belite Bio, Inc's (NASDAQ:BLTE) 49% Undervaluation?

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
VRDN

Business Wire

a year ago

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Enovix and Group14 Announce Collaboration to Develop Best-in-Class Silicon Batteries
VRDN

GlobeNewswire

a year ago

Enovix and Group14 Announce Collaboration to Develop Best-in-Class Silicon Batteries

3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
VRDN

Motley Fool

a year ago

3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond

Intellia to lay off staff, cut some early research
VRDN

BioPharma Dive

a year ago

Intellia to lay off staff, cut some early research

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
VRDN

Business Wire

a year ago

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Time to Buy These Top-Rated Security and Safety Services Stocks
VRDN

Zacks

a year ago

Time to Buy These Top-Rated Security and Safety Services Stocks

15 Best Earthquake Insurance Companies Heading into 2024
VRDN

Insider Monkey

a year ago

15 Best Earthquake Insurance Companies Heading into 2024

Salesforce upgraded, Chipotle downgraded: Wall Street's top analyst calls
VRDN

The Fly

a year ago

Salesforce upgraded, Chipotle downgraded: Wall Street's top analyst calls

Is M/I Homes, Inc.'s (NYSE:MHO) Latest Stock Performance A Reflection Of Its Financial Health?
VRDN

Simply Wall St.

a year ago

Is M/I Homes, Inc.'s (NYSE:MHO) Latest Stock Performance A Reflection Of Its Financial Health?

Do WaFd's (NASDAQ:WAFD) Earnings Warrant Your Attention?
VRDN

Simply Wall St.

a year ago

Do WaFd's (NASDAQ:WAFD) Earnings Warrant Your Attention?

VRDN

Business Wire

a year ago

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

These 8 Winning Bank Stocks Are 12% of My Portfolio. Here Is What I Think About All of Them.
VRDN

Motley Fool

a year ago

These 8 Winning Bank Stocks Are 12% of My Portfolio. Here Is What I Think About All of Them.

13 Penny Stocks that Captured the Attention of Billionaires
VRDN

Insider Monkey

a year ago

13 Penny Stocks that Captured the Attention of Billionaires

Victor Joseph Promoted to President & Chief Operating Officer of Mercury General Corporation
VRDN

PR Newswire

a year ago

Victor Joseph Promoted to President & Chief Operating Officer of Mercury General Corporation

Wall Street Analysts Think Afya (AFYA) Is a Good Investment: Is It?
VRDN

Zacks

a year ago

Wall Street Analysts Think Afya (AFYA) Is a Good Investment: Is It?

Should You Buy Tennant Company (NYSE:TNC) For Its Upcoming Dividend?
VRDN

Simply Wall St.

2 years ago

Should You Buy Tennant Company (NYSE:TNC) For Its Upcoming Dividend?

Viator Partners with Thoughtworks to Scale Power of Platforms to Enhance Traveler Experiences
VRDN

Business Wire

2 years ago

Viator Partners with Thoughtworks to Scale Power of Platforms to Enhance Traveler Experiences

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
VRDN

Business Wire

2 years ago

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

Equinox Gold's Greenstone Project: 96% Complete, Commissioning Underway
VRDN

Newsfile

2 years ago

Equinox Gold's Greenstone Project: 96% Complete, Commissioning Underway

VRDN

Business Wire

2 years ago

Grindr Brings Free At-Home HIV Self-Test Kits to Europe for the First Time With New Programs in Georgia and Ireland

Oil Price Tumbles Below $75 With Production at Record Levels
VRDN

Zacks

2 years ago

Oil Price Tumbles Below $75 With Production at Record Levels

Xenia Hotels & Resorts Declares Dividend For Fourth Quarter 2023 And Announces Board Approval For A $100 Million Increase In Share Repurchase Program
VRDN

PR Newswire

2 years ago

Xenia Hotels & Resorts Declares Dividend For Fourth Quarter 2023 And Announces Board Approval For A $100 Million Increase In Share Repurchase Program

Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress
VRDN

GuruFocus.com

2 years ago

Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress

VRDN

GuruFocus.com

2 years ago

Grindr Inc (GRND) Reports 39% Revenue Surge in Q3 2023, Ups Full-Year Outlook

VRDN

Business Wire

2 years ago

Grindr Inc. Reports Third Quarter 2023 Revenue Growth of 39%, Raises Guidance

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
VRDN

Business Wire

2 years ago

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

VRDN

Business Wire

2 years ago

Grindr Names Tolu Adeofe as Director of Investor Relations As It Approaches One Year Anniversary of its NYSE Listing

SFL - Third Quarter 2023 Results Presentation
VRDN

GlobeNewswire

2 years ago

SFL - Third Quarter 2023 Results Presentation

Brookfield Business Partners Reports Third Quarter 2023 Results
VRDN

GlobeNewswire

2 years ago

Brookfield Business Partners Reports Third Quarter 2023 Results

Share on Social Networks: